Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety
复制标题
DOI：
10.1016/j.ajog.2008.10.057
复制
发表时间：
2009-03-01
影响因子：
9.8
通讯作者：
Olivier, Sophie
中科院分区：
文献类型：
--
作者：
Archer, David F.;Dupont, Caroline M.;Olivier, Sophie
目的：本研究的目的是评估去甲文拉法辛的疗效和安全性研究设计：这是一项为期26周的双盲安慰剂对照试验，共有567名绝经后妇女参加（平均年龄53.7岁;自然绝经后4.8年）每周出现50次或更多潮热（HF），随机分配至去甲文拉法辛组（100或150 mg）或安慰剂组。在第4、12和26周时，将中重度HF的平均每日数量和平均每日HF严重程度与安慰剂相比，进行比较。结果：与安慰剂相比，100和150 mg去甲文拉法辛组在第4和12周时HF数量较基线显著减少（第12周减少：分别为60%、66%和47%;所有P
OBJECTIVE: The objective of the study was to assess the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for the treatment of vasomotor symptoms.STUDY DESIGN: This was a 26 week, double-blind, placebo-controlled trial of 567 postmenopausal women (mean age, 53.7 years; time since natural menopause, 4.8 years) experiencing 50 or more hot flushes (HFs) per week, randomly assigned to desvenlafaxine (100 or 150 mg) or placebo. Change from baseline in average daily number of moderate to severe HFs and average daily HF severity were compared with placebo at weeks 4, 12, and 26.RESULTS: A significantly greater decrease from baseline in number of HFs occurred at weeks 4 and 12 with 100 and 150 mg desvenlafaxine compared with placebo (week 12 reductions: 60%, 66%, and 47%, respectively; all P